TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36873868
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies targeting other tumor antigens or inhibitors preventing tumor antigenic escape
Study: 36873989
Drug: Belimumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab, dosage and duration not available
Study: 36873994
Drug: Methylone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone (200 mg)
Study: 37081574
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg once weekly
Study: 36875061
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of oncolytic vaccinia virus (1.00E+07 to 6.00E+09 PFU)
Study: 36875061
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of oncolytic vaccinia virus
Study: 36876350
Drug: First-line anti-TB
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol)
Study: 36876756
Drug: Transcatheter edge-to-edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge-to-edge repair plus medical therapy (device group)
Study: 36876756
Drug: Maximal doses
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal doses of guideline-directed medical therapy alone (control group)
Study: 36876740
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid (180 mg daily)
Study: 36876946
Drug: Telerehabilitation (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (TR) targeting arm motor function; 36 sessions of 70 minutes each over 6 weeks, half supervised via videoconference; included functional games, exercise videos, education, and daily assessments.
Study: 36877098
Drug: Sotatercept (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (0.3 mg/kg starting dose, 0.7 mg/kg target dose, subcutaneous every 3 weeks)
Study: 36877259
Drug: Backup insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Backup insulin regimens generated by the BP
Study: 36877259
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin dose, four-period basal insulin profile, short-acting meal doses, glucose correction factor
Study: 36877480
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), delivered weekly for 16 weeks
Study: 36877502
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (medical treatment with coronary angiography for recurrent ischemia; n=83)
Study: 36877575
Drug: Ophthalmic involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic involvement at diagnosis
Study: 36877575
Drug: Other ophthalmic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other ophthalmic abnormalities
Study: 36877726
Drug: Delaying factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delaying factors (consulting traditional, private and/or multiple providers, rural residence, prehospital intravenous therapy, and prehospital overnight stays)
Study: 36877726
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antibiotics reserved for hospital use, intravenous therapy, and prehospital overnight stays
Study: 36877807
Drug: Treat-to-target strategy
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target strategy (LDL-C target between 50 and 70 mg/dL)
Study: 36877807
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin treatment (rosuvastatin 20 mg or atorvastatin 40 mg)
Study: 36877964
Drug: Standard hemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hemostatic treatment
Study: 36878237
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks plus chemotherapy (paclitaxel 175 mg/m2)
Study: 36878237
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (paclitaxel 175 mg/m2)
Study: 36878897
Drug: Thermostable ID93
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermostable ID93 + GLA-SE vaccine
Study: 36878897
Drug: Non-thermostable two-vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermostable two-vial vaccine presentation
Study: 36879012
Drug: anti-EGFR-ILs-dox 50
Normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-EGFR-ILs-dox 50 mg/m²
Study: 36879078
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Eating Disorders (CBT-E)
Study: 36879107
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy in T1DM patients
Study: 36879129
Drug: Intravenous evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous evinacumab 15 mg/kg
Study: 36879292
Drug: Low-calorie food
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie food images versus baseline (L vs. X)
Study: 36879292
Drug: High-calorie food
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie food images versus low-calorie food images (H vs. L)
Study: 36879301
Drug: Mentalization-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based therapy (MBT)
Study: 36879386
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) use
Study: 36879424
Drug: Alirocumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab with statin therapy (after achieving very low LDL-C levels)
Study: 36879424
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with statin therapy
Study: 36880866
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp)
Study: 36880866
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin aspart (IAsp)
Study: 36881032
Drug: Olamkicept 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olamkicept 600 mg
Study: 36881032
Drug: Olamkicept 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olamkicept 300 mg
Study: 36881034
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (2 g)
Study: 36881446
Drug: Waitlist and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist and treatment-as-usual control
Study: 36881458
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to controller medication (inhaled corticosteroids)
Study: 36881542
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment for anemia and/or iron deficiency
Study: 36881542
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment for anemia and/or iron deficiency
Study: 36881780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IN-alert HF state and RDI ≥ 30 episodes/h
Study: 36882562
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline 100 mg twice daily for 12 months
Study: 36882736
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HR-/HER2- subtype
Study: 36882736
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HR+/HER2+ subtype (monotherapy)
Study: 36882736
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HR+/HER2+ subtype (combined therapies)
Study: 39437312
Drug: Deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg once daily
Study: 36883141
Drug: Cenicriviroc (CCR2/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CCR2/5 antagonist)
Study: 36883141
Drug: Icatibant (bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (bradykinin antagonist)
Study: 36883141
Drug: Apremilast (PDE4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (PDE4 inhibitor)
Study: 36883141
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (inhaled DNase)
Study: 36883141
Drug: Razuprotafib (Tie2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Razuprotafib (Tie2 agonist)
Study: 36883238
Drug: danavorexton 112
Normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: danavorexton 112 mg
Study: 36883362
Drug: Liraglutide (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (test drug)
Study: 36883379
Drug: Prescription sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription sleep medications (hypnotics)
Study: 36883379
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (therapist-led and digital)
Study: 36883885
Drug: Doxazosin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin, dosage and duration not specified
Study: 36884013
Drug: D2 antagonist
Normalized name: Dopamine receptor D2 antagonist-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2 antagonist amisulpride
Study: 36884024
Drug: Vortioxetine 5-10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 5-10 mg/day
Study: 36884024
Drug: Vortioxetine 15-20
Normalized name: vortioxetine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 15-20 mg/day
Study: 36884108
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous remifentanil at an initial dose of 1 μg/kg lean body weight (LBW), adjusted according to pain severity using the Dixon sequential method.
Study: 36884114
Drug: Surgery, target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, target therapy, and TNM stage
Study: 36884234
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus prednisone (20 mg/d for 3 months and 15 mg/d for 3 months)
Study: 36884323
Drug: Nirogacestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirogacestat (150 mg, oral, twice daily)
Study: 36888820
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution
Study: 36889160
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5-0.75mg/kg over 40 minutes, four doses over two weeks)
Study: 36889516
Drug: Nintedanib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib + prednisone taper
Study: 36889516
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + prednisone taper
Study: 36889610
Drug: MK-0616 6
Normalized name: vitamin MK 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0616 6 mg once daily
Study: 36889610
Drug: MK-0616 12
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0616 12 mg once daily
Study: 36889610
Drug: MK-0616 18
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0616 18 mg once daily
Study: 36889610
Drug: MK-0616 30
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0616 30 mg once daily
Study: 36889645
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation of vitamin B12 (1.8 μg) and folic acid (150 μg) for 6 months
Study: 36889826
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) treatment for hyperkalaemia, followed for 6 months.
Study: 36889827
Drug: Sleep quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep quality assessment during a 90-minute visit, evaluating determinants such as morbidity, lifestyles, psychological factors, socioeconomic variables, habitability conditions, screen time, relaxation techniques, and melatonin as a biological marker.
Study: 36890020
Drug: Mocetinostat 70
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 70 mg TIW plus durvalumab 1500 mg Q4W
Study: 36890393
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg per day for 7 days
Study: 36890529
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus tenoxicam injection (TX group)
Study: 36890535
Drug: Physician-administered injections
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-administered injections
Study: 36890535
Drug: Task-shifting (nurse-administered)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Task-shifting (nurse-administered)
Study: 36891030
Drug: Transmuscular quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmuscular quadratus lumborum block (TMQLB) with 0.4 ml/kg of 0.5% ropivacaine
Study: 36891030
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (PVB) with 0.4 ml/kg of 0.5% ropivacaine
Study: 36891077
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for 3 years
Study: 36891649
Drug: MI-CBT (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-CBT (Motivational Interviewing and Cognitive-Behavioral Therapy)
Study: 36891761
Drug: Postoperative anaemia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative anaemia (lowest haemoglobin concentration < 11 g dl -1)
Study: 36891761
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of postoperative anaemia and hypotension
Study: 36891995
Drug: Higher muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher muscle mass assessed by creatinine excretion rate
Study: 36892190
Drug: MW031 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MW031 (60 mg)
Study: 36892506
Drug: UDCA-Fenofibrate group
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UDCA-Fenofibrate group (fenofibrate at a daily dose of 200 mg in addition to UDCA)
Study: 36892506
Drug: UDCA-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA-only group (standard dose of UDCA)
Study: 36892677
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin and paclitaxel administration
Study: 36892677
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration (previously published data)
Study: 36892676
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m²
Study: 36892707
Drug: PAH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAH therapy escalation
Study: 36892753
Drug: Risankizumab 360
Normalized name: RISANKIZUMAB 360 mg in 2.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 360 mg
Study: 36892833
Drug: Regorafenib, ipilimumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D of regorafenib dosed at 80 mg daily, ipilimumab 1 mg/kg every 6 weeks, and nivolumab 240 mg every 2 weeks.
Study: 36892833
Drug: Regorafenib at
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond.
Study: 36892847
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1)
Study: 36892847
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg with standard-dose fulvestrant (arm 2)
Study: 36892884
Drug: Negative Affect
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Affect Treatment (NAT)
Study: 36893453
Drug: TPO-RA discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPO-RA discontinuation
Study: 36893785
Drug: nvHAP prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: nvHAP prevention bundle (oral care, dysphagia screening and management, mobilisation, discontinuation of non-indicated proton-pump inhibitors, respiratory therapy)
Study: 36893784
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 1a)
Study: 36893784
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral praziquantel 40 mg/kg (cohort 1b)
Study: 36893784
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 2)
Study: 36893784
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral arpraziquantel 50 mg/kg (cohort 3)
Study: 36893784
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral arpraziquantel 60 mg/kg (cohort 4b)
Study: 36893935
Drug: KE+CHO (573
Approvals — FDA: no, EMA: no, PMDA: no
Description: KE+CHO (573 mg KE/kg body mass plus 110 g glucose)
Study: 36893935
Drug: CHO (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (110 g glucose)
Study: 36894201
Drug: Comprehensive menstrual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive menstrual health (MH) intervention including education, support, analgesics, and menstrual products.
Study: 36894239
Drug: Acellular carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular carbohydrate sources (e.g., flour-based whole-grain products)
Study: 36894250
Drug: HIGH carotenoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH carotenoid intake (13.1 mg daily)
Study: 36894250
Drug: MED carotenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED carotenoid intake (13.1 mg daily)
Study: 36894250
Drug: LOW carotenoid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW carotenoid intake (13.1 mg daily)
Study: 36894810
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered indocyanine green (ICG)
Study: 36894877
Drug: POC targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: POC targeted coagulopathy management and intraoperative administration of 5% albumin
Study: 36894940
Drug: Standardised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised treatment package for first-episode depression
Study: 36895062
Drug: Non-anthracycline HER2-targeted
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anthracycline HER2-targeted treatment regimen with echocardiograms every 6 months
Study: 36895163
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy (FT) using cryotherapy
Study: 36896716
Drug: In-hospital observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital observation on oral diuretics (OOD)
Study: 36896967
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment of malaria (ISTp)
Study: 36897008
Drug: DPMAS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPMAS with sequential low-volume plasma exchange (LPE)
Study: 36897008
Drug: Comprehensive medical
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medical treatment (Control)
Study: 36897140
Drug: Scheduled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intravenous ketorolac (30 mg every 6 hours)
Study: 36897140
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mg every 6 hours)
Study: 36897140
Drug: Scheduled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intravenous ketorolac
Study: 36897140
Drug: Scheduled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intravenous ketorolac and Placebo
Study: 36897226
Drug: Tablet-based contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based contraception education intervention